🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating around the world, with estimates suggesting more than 82 million infections annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

Based on results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The study enrolled nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals directly involved have voiced hope. Access to a one-pill regimen such as this is hailed as a "game-changer" for public health efforts. This is deemed crucial to alleviate the strain of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.